Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 21;64(5):e02548-19.
doi: 10.1128/AAC.02548-19. Print 2020 Apr 21.

Synergistic Interactions of Indole-2-Carboxamides and β-Lactam Antibiotics against Mycobacterium abscessus

Affiliations

Synergistic Interactions of Indole-2-Carboxamides and β-Lactam Antibiotics against Mycobacterium abscessus

Clément Raynaud et al. Antimicrob Agents Chemother. .

Abstract

New drugs or therapeutic combinations are urgently needed against Mycobacterium abscessus Previously, we demonstrated the potent activity of indole-2-carboxamides 6 and 12 against M. abscessus We show here that these compounds act synergistically with imipenem and cefoxitin in vitro and increase the bactericidal activity of the β-lactams against M. abscessus In addition, compound 12 also displays synergism with imipenem and cefoxitin within infected macrophages. The clinical potential of these new drug combinations requires further evaluation.

Keywords: MmpL3; Mycobacterium abscessus; drug synergism; indole-2-carboxamide; macrophage; therapeutic activity; β-lactam.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Structures of imipenem, cefoxitin, and the lead indole carboxamides 6 and 12 used in this study.
FIG 2
FIG 2
Synergistic activity of indole-2-carboxamide derivatives with IPM and FOX in vitro. CFU counts of Cpd12 (A) and Cpd6 (B) given alone and in combination with imipenem (IPM) or cefoxitin (FOX). M. abscessus cultures were incubated at 30°C in CaMHB for 5 days in the presence of the indicated compounds (μg/ml) and plated on LB agar prior to CFU enumeration. (C) For CFU determination, the M. abscessus mutant A309P (spontaneous resistant strain to Cpd12 carrying the A309P mutation in MmpL3) was exposed to the indicated antibiotics (μg/ml) at 30°C in CaMHB for 5 days. Graphs represent the mean of three independent experiments completed in triplicate. Data are expressed as the mean ± standard deviation (SD). The statistical test used is a nonparametric Mann-Whitney t test in which the combinations were compared to the drugs alone. ns, nonsignificant; **, P 0.01; ***, P 0.001.
FIG 3
FIG 3
CFU determination of clinical isolates exposed to Cpd12 given alone or in combination with imipenem (IPM) or cefoxitin (FOX). M. abscessus cultures were incubated at 30°C in CaMHB for 5 days in the presence of the indicated compounds (μg/ml) and plated on LB agar prior to CFU enumeration. Data are expressed as the mean ± SD from three independent experiments completed in triplicate. The statistical test used is a nonparametric Mann-Whitney t test in which the combinations were compared to the drugs alone. *, P 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P < 0.0001.
FIG 4
FIG 4
Impact of Cpd12 alone or in combination on intracellular-residing M. abscessus. THP-1 macrophages were infected with M. abscessus S expressing TdTomato (multiplicity of infection [MOI] of 2:1) and treated with the indicated compounds (μg/ml). (A) CFU were determined at day 0 and day 2 postinfection. Data represents the mean ± SD of three independent experiments completed in triplicate. For statistical analysis, a nonparametric Mann-Whitney t test was performed. ***, P ≤ 0.001; ****, P < 0.0001. (B) Percentage of infected THP-1 macrophages at day 0 and day 2 postinfection. Data shown are mean values ± SD for one representative experiment completed in triplicate. One-way analysis of variance (ANOVA) Kruskal-Wallis was used as a statistical test. ****, P < 0.0001. (C) Immunofluorescent fields were taken at day 2 postinfection at magnification 40× (using confocal microscopy) showing the nuclei of macrophages (DAPI in blue) infected with red-fluorescent M. abscessus in the absence or in the presence of the drugs used alone or in combination. Yellow arrows emphasize red-fluorescent M. abscessus (tdTomato) within macrophages. Only intracellular bacteria that were individually observed under the microscope were recorded.

Similar articles

Cited by

References

    1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Winthrop K, ATS Mycobacterial Diseases Subcommittee, American Thoracic Society, Infectious Disease Society of America. 2007. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175:367–416. doi:10.1164/rccm.200604-571ST. - DOI - PubMed
    1. Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann J-L, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS. 2016. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. Thorax 71:88–90. doi:10.1136/thoraxjnl-2015-207983. - DOI - PMC - PubMed
    1. Brode SK, Daley CL, Marras TK. 2014. The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review. Int J Tuber Lung Dis 18:1370–1377. doi:10.5588/ijtld.14.0120. - DOI - PubMed
    1. Li W, Yazidi A, Pandya AN, Hegde P, Tong W, Calado Nogueira de Moura V, North EJ, Sygusch J, Jackson M. 2018. MmpL3 as a target for the treatment of drug-resistant nontuberculous mycobacterial infections. Front Microbiol 9:1547. doi:10.3389/fmicb.2018.01547. - DOI - PMC - PubMed
    1. Dupont C, Viljoen A, Dubar F, Blaise M, Bernut A, Pawlik A, Bouchier C, Brosch R, Guérardel Y, Lelièvre J, Ballell L, Herrmann J-L, Biot C, Kremer L. 2016. A new piperidinol derivative targeting mycolic acid transport in Mycobacterium abscessus. Mol Microbiol 101:515–529. doi:10.1111/mmi.13406. - DOI - PubMed

Publication types

MeSH terms